Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Kiniksa Pharmaceuticals’ 200-page disclosures can feel like reading lab notes in another language. Clinical trial protocols, ARCALYST revenue footnotes, and intricate risk factors are scattered across multiple forms—yet timing these details is critical when a single Phase 2 update can move the stock overnight.
Our platform turns that maze into a map. Stock Titan’s AI-powered summaries translate each Kiniksa Pharmaceuticals annual report 10-K simplified into plain English, highlight cash-burn trends in every Kiniksa Pharmaceuticals quarterly earnings report 10-Q filing, and flag Kiniksa Pharmaceuticals 8-K material events explained within minutes of hitting EDGAR. Need real-time signals? We stream Kiniksa Pharmaceuticals Form 4 insider transactions real-time so you can monitor executive confidence before key data drops. The result: you spend minutes, not hours, uncovering what matters.
- Track Kiniksa Pharmaceuticals insider trading Form 4 transactions and spot buying or selling patterns.
- Dive into Kiniksa Pharmaceuticals proxy statement executive compensation to see how milestones shape pay packages.
- Compare segments with a click using our Kiniksa Pharmaceuticals earnings report filing analysis.
Whether you’re understanding Kiniksa Pharmaceuticals SEC documents with AI for the first time or need a refresher before a call, our expert analysis covers every form type—10-K, 10-Q, 8-K, S-1, and more. Receive alerts the moment a Kiniksa Pharmaceuticals executive stock transactions Form 4 posts, and let our algorithm spotlight the trial endpoints, cash runway, and material agreements that drive valuation. Complex biotech filings, explained simply, updated in real time—so you can act with confidence.
Mind Medicine (MindMed) Inc. (MNMD) has filed a Form 144, signaling the planned sale of 26,491 common shares. The shares—acquired on 06/25/2025 through the vesting of restricted stock granted under a company plan—are to be sold through Morgan Stanley Smith Barney LLC. Based on an aggregate market value of $180,210.33, the filing values the shares at roughly $6.80 each.
The proposed sale represents a de-minimis 0.035 % of the company’s 75,553,266 shares outstanding and is scheduled to occur on or after 06/25/2025 on the NASDAQ. No additional share sales by the same party were reported for the past three months, and no material adverse information is claimed by the seller in accordance with Rule 144 representations.
Because Form 144 filings merely notify the market of an intent to sell and do not guarantee execution, the practical impact is usually limited unless the size is significant or the seller is a key insider. Given the relatively small volume and lack of prior sales, this notice appears routine and unlikely to materially affect MNMD’s float or share-price dynamics.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the primary focus of Kiniksa Pharmaceuticals?
Which key products are part of Kiniksa's portfolio?
How does Kiniksa generate revenue?
What distinguishes Kiniksa's approach in the biopharmaceutical industry?
What types of diseases does Kiniksa target?
What stage of development are Kiniksa's products in?
How does Kiniksa enhance its clinical development processes?
How does Kiniksa maintain its market and scientific credibility?
